Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
JIB
GLOBETECH PUBLISHING

Bacteria’s Self-Defense Mechanisms Revealed

By BiotechDaily International staff writers
Posted on 24 Sep 2012
Image: The toxins normally bind very strongly to the antitoxins and are thus not only inactive, but also prevent the production of more toxin from the information encoded in the bacterial DNA. During the dormant state, however, the antitoxins are degraded, and the toxins released (step 1). The free toxins now bind to unoccupied antitoxins on DNA within the area encoding the toxin-antitoxin couple (step 2). Binding increasing amounts of toxin eventually leads to the release of the molecules from the gene (steps 3 and 4) and finally to new toxin production (Photo courtesy of Ditlev E. Brodersen).
Image: The toxins normally bind very strongly to the antitoxins and are thus not only inactive, but also prevent the production of more toxin from the information encoded in the bacterial DNA. During the dormant state, however, the antitoxins are degraded, and the toxins released (step 1). The free toxins now bind to unoccupied antitoxins on DNA within the area encoding the toxin-antitoxin couple (step 2). Binding increasing amounts of toxin eventually leads to the release of the molecules from the gene (steps 3 and 4) and finally to new toxin production (Photo courtesy of Ditlev E. Brodersen).
Danish researchers have gleaned new insights into how bacteria control the amount of toxin in their cells. The new findings can ultimately lead to the development of novel forms of treatment for bacterial infections.

Many pathogenic bacteria are able to go into a dormant state by making persister cells that are not receptive to conventional antibiotics. This causes serious problems in the treatment of life-threatening disorders such as tuberculosis, where the presence of persister cells often leads to a resurgence of infection following medical treatment.

At the molecular level, the formation of persister cells is due to the presence of toxins that are produced by the bacteria themselves, and which enable them to enter the dormant state. During this hibernation period, the bacteria constantly regulate the amount of toxin at exactly the same level and thus maintain the dormant state.

In an article published online August 20, 2012, in the American scientific journal Structure, the researchers from the department of molecular biology and genetics, Aarhus University (Aarhus, Denmark), new findings that reveal the molecular particulars of the regulatory mechanism of toxins.

By isolating and crystallizing the toxin molecules and their molecular companions--the antitoxins--and by subsequently exposing the crystals to strong X-rays, the scientists gained unique insight into how bacteria control the amount of toxin in the cell.

The new findings can eventually lead to the development of completely new forms of treatment of bacterial infections that work at first by blocking toxin function and production, and consequently by using conventional antibiotics to fight the pathogenic bacteria.

Related Links:
Aarhus University


comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Illustration of the apoER2 receptor protein shows the structure of the entire protein in detail (Photo courtesy of Wikimedia Commons).

Risk of Cardiovascular Disease Linked to Apolipoprotein E Variants

The apoE4 variant form of circulating apolipoprotein E (apoE) leads to increased risk of cardiovascular disease by blocking binding of the normal apoE3 form to the apoliprotein E receptor 2 (apoER2) in... Read more

Drug Discovery

view channel
Image: S-649266 has more robust antibacterial activity than established antibiotics against multidrug-resistant bacteria (Photo courtesy of Shionogi).

Novel Antibiotic Shows Potential for Broad Range of Infections

The emergence of bacterial resistance to known antibacterial agents is becoming a major challenge in treating the infection caused by multi drug resistant (MDR) bacteria. In order to treat bacterial... Read more

Business

view channel

Collaboration of Mayo Clinic and IBM Cognitive Computer Devised to Improve Clinical Trial Research

The Mayo Clinic (Rochester, MN, USA) and IBM (Armonk, NY, USA) recently announced plans to pilot Watson, the IBM cognitive computer, to match patients more rapidly with suitable clinical trials. A proof-of-concept phase is currently ongoing, with the intent to introduce it into clinical use in early 2015.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.